Page 145 - NobleCon19revC2_Neat

Onconova Therapeutics, Inc.

SELECTED FINANCIAL ITEMS ONTX

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue 0.06 0.06 0.06 0.06 0.23
Gross Profit 0.06 0.06 0.06 0.06 0.23
Gross Margin 100% 100% 100% 100% 100%
EBIT (5.73) (6.14) (4.61) (5.09) (21.57)
EBIT Margin -10239% -10959% -8088% -8928% -9544%
Net Income to Common Shareholders (5.42) (5.78) (4.25) (4.74) (20.18)
Net Margin -9679% -10313% -7456% -8314% -8931%

Balance Sheet Key Items
Total Assets 39.37 35.06 30.47 27.04 27.04
Cash & Short Term Investments 38.76 34.22 29.73 25.24 25.24
% of Assets 98% 98% 98% 93% 93%
Current Assets -Total 39.35 35.04 30.45 27.01 27.01
% of Assets 100% 100% 100% 100% 100%
Total Liabilities 11.06 12.19 11.57 12.52 12.52
% of Assets 28% 35% 38% 46% 46%
Current Liabilities - Total 8.05 9.22 8.67 9.67 9.67
% of Assets 20% 26% 28% 36% 36%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 28.31 22.88 18.90 14.52 14.52
% of Assets 72% 65% 62% 54% 54%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (3.88) (4.54) (4.49) (4.47) (17.39)
Net Cash Flow - Investing NA NA NA (0.01) (0.01)
Net Cash Flow - Financing NA NA NA NA 0.00

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference